LEGN Research and Charts

LEGN - Legend Biotech Corp ADR (Healthcare: Biotechnology)

Projected Earnings Date: 2026-02-11 (Delayed quote data 2026-02-10)

Last 17.91	Change ⇑ +0.72 (+4.19%)	Volume 2,778,400
	Open 17.38	High 18.14	Low 17.20

8EMA (Daily) 17.48	40EMA (Daily) 20.83	50EMA (Daily) 21.76	STO (Daily) 15.880	MACD Hist (Daily) 0.195
8EMA (Weekly) 20.084	40EMA (Weekly) 28.84	50EMA (Weekly) 30.52	STO (Weekly) 6.158	MACD Hist (Weekly) -0.417


Company Profile
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.